US Bancorp’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
Other funds holding RXRX
AIM
MCMU
US Bancorp's RXRX Position: Q2 2026 in Review
US Bancorp reduced its Recursion Pharmaceuticals (RXRX) stake by 11% in Q2 2026, selling an estimated $5.94K and leaving 15,157 shares worth $55.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2737.
US Bancorp first reported a position in RXRX in Q2 2022 and has held it in 13 quarters since. The position peaked at $172K in Q3 2022. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.
- US Bancorp held 15,157 shares of Recursion Pharmaceuticals worth $55.6K as of Q2 2026.
- US Bancorp sold 1,783 Recursion Pharmaceuticals shares in Q2 2026, an estimated $5.94K.
- Recursion Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #2737 holding.
- US Bancorp first reported a position in Recursion Pharmaceuticals in Q2 2022 and has held it in 13 quarters since.
- US Bancorp's Recursion Pharmaceuticals position peaked at $172K in Q3 2022.
- 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.
Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.